|Articles|January 1, 2006

Pharmacy Times

  • Volume 0
  • 0

TAUZIN DEFENDS DIRECT-TO-CONSUMER Rx ADVERTISING

While the FDA takes a fresh look at theimpact of direct-to-consumer (DTC)advertising of prescription drugs, manufacturersof prescription medicines saythe evidence supporting the value ofthese ads is clear-cut. "There is no doubtthat DTC advertising is an invaluable communicationstool that empowers millionsof Americans to talk to health care professionalsabout their medical conditions," Pharmaceutical Research andManufacturers of America President andChief Executive Officer Billy Tauzin said.

Tauzin, a former congressman activelyinvolved in health care issues, arguedthat consumer ads for prescription productsgive physicians an opportunity todiscuss the risks and benefits of coursesof treatments—a dialogue that producesmore informed patients.

"The educational value of DTC advertisingis particularly important to addressunderdiagnosis and undertreatment ofmajor medical conditions such as asthma,cerebral vascular disease, diabetes,and hypertension," he said.

Articles in this issue

almost 20 years ago

High Alert Insulin Bin

almost 20 years ago

Hydase (hyaluronidase injection, USP)

almost 20 years ago

Humira (adalimumab)

almost 20 years ago

INVANZ (ertapenem for injection)

almost 20 years ago

Compounding HOTLINE

almost 20 years ago

Can You Read These Rxs?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME